Treating early-stage Hodgkin lymphoma in resource-limited settings: InPOG-HL-15-01 experience,Pediatric Blood & Cancer

当前位置： X-MOL 学术 › Pediatr. Blood Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Treating early-stage Hodgkin lymphoma in resource-limited settings: InPOG-HL-15-01 experience
Pediatric Blood & Cancer ( IF 2.4 ) Pub Date : 2021-07-22 , DOI: 10.1002/pbc.29219
Amita Mahajan ₁ , Manisha Singh ₂ , Sameer Bakhshi ₃ , Sandeep Jain ₄ , Venkatraman Radhakrishnan ₅ , Nishant Verma ₆ , Rachna Seth ₇ , Ramandeep Singh Arora ₈ , Veronique Dinand ₉ , Manas Kalra ₁₀ , Piali Mandal ₁₁ , Gauri Kapoor ₄ , Mohammad Sajid ₂ , Sanjay Thulkar ₁₂ , Ashima Arora ₇ , Ankit Taluja ₁₃ , Jagdish Chandra ₁₁

Affiliation

Department of Pediatric Oncology, Indraprastha Apollo Hospital, New Delhi, India.
Department of Medical and Pediatric Oncology, Mahavir Cancer Sansthan, Patna, India.
Department of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India.
Department of Pediatric Oncology, Rajiv Gandhi Cancer Institute, New Delhi, India.
Department of Pediatric Oncology, Cancer Institute-Adyar, Chennai, India.
Department of Pediatrics, King George's Medical University, Lucknow, India.
Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Department of Pediatric Oncology, Max Super Specialty Hospital, New Delhi, India.
Department of Palliative and Supportive Unit, BJ Wadia Hospital, Mumbai, India.
Department of Pediatric Oncology, Sir Ganga Ram Hospital, New Delhi, India.
Department of Pediatrics, Kalawati Saran Children's Hospital, New Delhi, India.
Department of Radiology, All India Institute of Medical Sciences, New Delhi, India.
Cankids Kidscan, New Delhi, India.

Hodgkin lymphoma (HL) in childhood is an eminently curable disease. Excellent outcomes can be achieved even in resource-limited settings and increasingly, the focus is on limiting long-term toxicity. Contemporary treatment incorporates a risk-stratified, response-adapted approach using multiagent chemotherapy with or without low-dose radiotherapy (RT). Many developing countries continue to use ABVD (adriamycin, bleomycin, vinblastin, and dacarbazine)-based regimen owing to limited acute toxicity, cost, and ease of delivery. We report outcomes of children with early-stage HL using limited cycles of ABVD-based treatment in the first prospective multicentric collaborative study from India InPOG-HL-15-01.

更新日期：2021-08-23

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11